Kathleen A Leppig

List of Publications by Year
in descending order

31 papers	2,082 citations	516710 16 h-index	501196 28 g-index
33 all docs	33 docs citations	33 times ranked	3245 citing authors

#	Article	IF	Citations
1	Using Protection Motivation Theory to Predict Intentions for Breast Cancer Risk Management: Intervention Mechanisms from a Randomized Controlled Trial. Journal of Cancer Education, 2023, 38, 292-300.	1.3	2
2	Do research participants share genomic screening results with family members?. Journal of Genetic Counseling, 2022, 31, 447-458.	1.6	12
3	The reckoning: The return of genomic results to 1444 participants across the eMERGE3 Network. Genetics in Medicine, 2022, 24, 1130-1138.	2.4	12
4	Returning negative results from <scp>largeâ€scale</scp> genomic screening: Experiences from the <scp>eMERGE III</scp> network. American Journal of Medical Genetics, Part A, 2021, 185, 508-516.	1.2	5
5	Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial. JNCI Cancer Spectrum, 2021, 5, pkaa114.	2.9	4
6	Preferences of biobank participants for receiving actionable genomic test results: results of a recontacting study. Genetics in Medicine, 2021, 23, 1163-1166.	2.4	4
7	Penetrance of Breast Cancer Susceptibility Genes from the eMERGE III Network. JNCI Cancer Spectrum, 2021, 5, pkab044.	2.9	14
8	Patient and Family Preferences on Health System-Led Direct Contact for Cascade Screening. Journal of Personalized Medicine, 2021, 11, 538.	2.5	17
9	Effect of a Randomized Trial of a Web-Based Intervention on Patientâ€“Provider Communication About Breast Density. Journal of Women's Health, 2021, 30, 1529-1537.	3.3	0
10	Participant choices for return of genomic results in the eMERGE Network. Genetics in Medicine, 2020, 22, 1821-1829.	2.4	25
11	Returning Results in the Genomic Era: Initial Experiences of the eMERGE Network. Journal of Personalized Medicine, 2020, 10, 30.	2.5	39
12	Frequency of genomic secondaryÂfindings among 21,915 eMERGE network participants. Genetics in Medicine, 2020, 22, 1470-1477.	2.4	61
13	Characteristics Associated with Participation in ENGAGED 2 â€“ A Web-based Breast Cancer Risk Communication and Decision Support Trial. , 2020, 24, 1-4.		4
14	Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. American Journal of Human Genetics, 2019, 105, 588-605.	6.2	99
15	â€œIt would be so much easierâ€¦ health system-led genetic risk notificationâ€”feasibility and acceptability of cascade screening in an integrated system. Journal of Community Genetics, 2019, 10, 461-470.	1.2	8
16	Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants. Genetics in Medicine, 2018, 20, 1175-1185.	2.4	133
17	A Report on Ten Asia Pacific Countries on Current Status and Future Directions of the Genetic Counseling Profession: The Establishment of the Professional Society of Genetic Counselors in Asia. Journal of Genetic Counseling, 2018, 27, 21-32.	1.6	24
18	Ethical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience. Journal of Personalized Medicine, 2018, 8, 2.	2.5	44

#	Article	IF	Citations
19	Harmonizing Outcomes for Genomic Medicine: Comparison of eMERGE Outcomes to ClinGen Outcome/Intervention Pairs. Healthcare (Switzerland), 2018, 6, 83.	2.0	18
20	Collaborations in medical genetics: 10â€Year history of an ongoing Vietnameseâ€North American Collaboration. Molecular Genetics & Genomic Medicine, 2018, 6, 129-133.	1.2	2
21	A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system. Contemporary Clinical Trials, 2017, 56, 25-33.	1.8	14
22	Building a family network from genetic testing. Molecular Genetics & Genomic Medicine, 2017, 5, 122-129.	1.2	4
23	The genomic landscape of balanced cytogenetic abnormalities associated with human congenital anomalies. Nature Genetics, 2017, 49, 36-45.	21.4	251
24	Improving performance of multigene panels for genomic analysis of cancer predisposition. Genetics in Medicine, 2016, 18, 974-981.	2.4	80
25	Prospective participant selection and ranking to maximize actionable pharmacogenetic variants and discovery in the eMERGE Network. Genome Medicine, 2015, 7, 67.	8.2	23
26	A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muirâ€“Torre variant of Lynch syndrome. Genetics in Medicine, 2014, 16, 711-716.	2.4	104
27	Phenotype and X inactivation in 45,X/46,X,r(X) cases. American Journal of Medical Genetics Part A, 2004, 128A, 276-284.	2.4	26
28	Ring X and Other Structural X Chromosome Abnormalities: X Inactivation and Phenotype. Seminars in Reproductive Medicine, 2001, 19, 147-158.	1.1	55
29	Trisomy 10p: Report of an unusual mechanism of formation and critical evaluation of the clinical phenotype. , 1996, 65, 197-204.		20
30	DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell, 1993, 72, 143-151.	28.9	784
31	Predictive value of minor anomalies. I. Association with major malformations. Journal of Pediatrics, 1987, 110, 531-537.	1.8	194